Cholesterol Metabolism in Plasma and Interstitial Fluid Among Subjects Undergoing Hemodialysis.
Key facts
- Who runs it
- Karolinska University Hospital
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 20 people, planned
- Started
- 17 Apr 2019
- Expected to end
- 31 Dec 2027
- Type of study
- Observational, 4 groups
- Record updated
- 19 March 2025
- Why it stopped
- Covid19
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Diabetic nephropathy, because of type 2 diabetes, undergoing hemodialysis and subjects with chronic kidney disease of other causes undergoing hemodialysis
Who cannot take part
- Treatment with Warfarin due to increased risk of Calciphylaxis (calcific uremic arteriolopathy, CUA)
- Active infection that increases the risk of secondary infection in the skin where the vesicles containing interstitial fluid have been emptied of interstitial fluid with a fine needle and the bladder roof is intact
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Because the atherosclerosis process partly occur in the intercellular space of the vessel wall, the determination of the constitution of lipoproteins in the interstitial fluid may expand the knowledge about the atherosclerosis process and lead to a better understanding of what constitutes the increased risk of developing cardiovascular disease in patients with chronic diseases. The investigators hypothesize that the apoB-containing particles in T2D patients are more susceptible to be retained or consumed in the intercellular compartment, which in turn could be one explanation for the elevated risk of atherosclerosis. The investigators hypothesise that with the progression of chronic kidney disease this process is further increased. Patients undergoing dialysis are known to have a very high risk of cardiovascular disease. The investigators now want to study the cholesterol metabolism in interstitial fluid in subjects undergoing hemodialysis because of diabetic nephropathy and in subjects undergoing hemodialysis because of chronic kidney disease of other causes.
The 4 groups in the trial
- Diabetic nephropathy, on hemodialysis
- Chronic kidney disease, on hemodialysis
Chronic kidney disease of other causes than Diabetes.
- Chronic kidney disease, predialysis
Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
- Diabetic nephropathy, predialysis
Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 19 March 2025